Key facts
- Poolbeg Pharma is trialing an oral drug named POLB 001.
- The trials are taking place at six NHS hospitals.
- POLB 001 aims to prevent cytokine release syndrome (CRS).
- CRS is a potentially fatal side-effect of cancer immunotherapy.
- The drug is intended to make cancer treatments safer.
- The drug may reduce healthcare costs by allowing treatment outside specialist centers.
Poolbeg Pharma, a London-based startup, is currently conducting trials for its oral drug, POLB 001, across six National Health Service (NHS) hospitals. The primary objective of this trial is to assess the drug's efficacy in preventing cytokine release syndrome (CRS). CRS is a potentially fatal side-effect that can arise from cancer immunotherapy treatments, a class of therapies that harness the patient's immune system to fight cancer. By aiming to prevent CRS, POLB 001 seeks to enhance the safety profile of these advanced cancer treatments. Furthermore, the drug's development is motivated by the potential to reduce healthcare expenditures. The company believes that if POLB 001 proves effective, it could allow patients to be treated in less specialized settings, thereby lowering the overall cost of care and potentially increasing access to these life-saving therapies. The trial at NHS hospitals is a crucial phase in determining the drug's viability and its impact on patient outcomes and healthcare system efficiency.